BDSX News and Press, Biodesix Inc. From 04/12/22

Biodesix (BDSX) +53%. Actinium Pharmaceuticals ATNM +44% on agreement with Immedica Pharma for conditioning agent. BioCardia BCDA +34% after FDA nod to begin trial of BCDA-04 in COVID patients. Aeglea BioTherapeutics AGLE +19% on filing seeking FDA approval of pe...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips It’s time for another dive into the market this morning with a look at the biggest pre-market stock movers for Tuesday! Source: f11photo/Shutterstock.com We’ve got a reverse stock split, clinical trial...

Biodesix (NASDAQ:BDSX) raised $11.7M through sale of 6,508,376 common shares on April 7, 2022 in a private placement. Net proceeds will be utilized to fund the partial repayment of its existing term loan and general corporate purposes, including our strategic growth. The Company reaffirm...

Additionally, data associated with the GeneStrat ® ddPCR ™ and Genestrat NGS ™ blood tests will be presented at the American Association for Cancer Research (AACR) Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions co...

Biodesix, Inc. (BDSX) Q4 2021 Earnings Conference Call March 14, 2022 8:30 a.m. ET Company Participants Scott Hutton - President & CEO Robin Harper Cowie - CFO Chris Brinzey - IR Conference Call Participants Brian Weinstein - William Blair Kyle Mikson - Canaccord Genuity Yuko Oku - Morgan...

Image source: The Motley Fool. Biodesix, Inc. (NASDAQ: BDSX) Q4 2021 Earnings Call Mar 14, 2022 , 8:30 a.m. ET Operator Continue reading For further details see: Biodesix, Inc. (BDSX) Q4 2021 Earnings Call Transcript

Biodesix press release (NASDAQ:BDSX): Q4 GAAP EPS of -$0.49 in-line. Revenue of $7.22M (-73.3% Y/Y) beats by $0.02M. 2022 Financial Outlook: The Company anticipates generating between $37.5 million to $39.5 million in total revenue in 2022 vs consensus of $36.38M. For further details s...

Fourth Quarter and Fiscal Year 2021 Lung Diagnostic Revenue of $5.4 Million and $18.7 Million Increased 48% and 49% over the comparable 2020 periods, respectively Full-Scale Launch of GeneStrat NGS™ Test in January 2022 Conference Call and Webcast Today at 8:30 ...

Biodesix (NASDAQ:BDSX) entered into a purchase agreement for the issue and sale of its stock, from time to time, of up to $50M with institutional investor Lincoln Park Capital Fund. BDSX will have the right at its sole discretion, but not the obligation, to sell to LPC up to $50M worth of sto...

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced it has entered into a purchase agreement for the issuance and sale of its common stock, from time to time, of up to $50 million with Lincoln Park Capital F...